Too early in the launch to critque. I sure hope they plan on some direct to consumer advertising and don't rely solely on the reps. There are a lot of prospective patients that don't frequent a GI specialist on a regular basis, if at all. Some advertising would probably help the stock as well.
If the drug sales go well,the short position should finally dissipate. A hostile takeover might be in order if sales lag Linzess badly. Shame we don't know if there has been interest in partnership or buyout.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.